

Marpai Inc. (MRAI:OTC)

March 17, 2025


All figures in USD unless otherwise stated

Marpai Inc.	MRAI:OTC
Share Price	\$0.91
Average Daily Volume (K)	97.7
Shares Outstanding (M)	13.7
Market Cap (\$M)	\$12.5
Cash (\$M)	\$0.8
Debt (\$M)	\$29.9
Enterprise Value (\$M)	\$41.6

FYE Dec 31	2022A	2023A	LTM
Sales (\$M)	\$24.3	\$37.2	\$30.3
Sales Growth (YoY %)	71%	53%	(16%)
Gross Margin (%)	30%	35%	31%
EBITDA (\$M)	(\$25.5)	(\$24.9)	(\$14.6)
EBITDA Margin (%)	(105%)	(67%)	(48%)
Net Income (\$M)	(\$26.5)	(\$28.8)	(\$26.0)

Valuation	2022A	2023A	LTM
EV/EBITDA	N/A	N/A	N/A
P/E	N/A	N/A	N/A
EV/Sales	1.7x	1.1x	1.4x

Please refer to the applicable disclosures on the back page
Source: Atrium Research, CapitalIQ, Company Documents



Marpai is a technology platform company which operates subsidiaries that provide TPA and value-oriented health plan services to employers that directly pay for employee health benefits. Operating nationwide, Marpai offers access to leading provider networks including Aetna and Cigna, industry leading Reference Based Pricing (RBP) solutions and all TPA services.

What you need to know:

- Marpai specializes in AI-powered third-party administration (TPA) services for self-funded health plans.
- The Company is undergoing a turnaround with a new leadership team, focusing on restarting revenue growth and cutting costs.
- Marpai operates in a large addressable market of \$22B including 165M Americans on employer health plans, of which 64% are self-funded.
- Watch clips of the interview [here](#).

Company Overview

Marpai, Inc. is a technology-driven healthcare company specializing in AI-powered third-party administration (TPA) services for self-funded health plans. By leveraging machine learning and predictive analytics, Marpai helps employers optimize healthcare costs while improving health outcomes for their employees. The Company's platform utilizes data-driven insights to anticipate potential health risks, enhance care coordination, and reduce unnecessary medical expenses. Through its innovative approach, Marpai aims to transform the traditional health benefits model by making healthcare more proactive, transparent, and efficient.

Headquartered in Tampa, Florida, Marpai serves employers, brokers, and healthcare providers across the U.S., offering a comprehensive suite of administrative and cost-containment solutions. The Company's technology-driven platform integrates AI with claims processing, member engagement, and provider network management, streamlining operations and improving the overall healthcare experience.

Investment Thesis

Large Addressable Market. Employer health plans cover 165M Americans and 64% are self-funded, creating a >\$22B industry. Marpai brings deep learning and data analytics to the rapidly growing, low-tech TPA sector to deliver affordable and intelligent healthcare to employers and their health plan members.

Restarting Growth. Management is attempting to reinvigorate topline growth by adding to its sales team and signing new clients such as a 4,000 employee restaurant group, a 6,000 employee hospital group, and housing industry clients with 3,400 employees.

Cutting Costs. In Q3, operating expenses decreased 36% YoY compared to revenue which declined 20% YoY. The Company continues to push towards profitability.

New Leadership. The team is led by CEO & Director Damien Lamendola, who took on the role in November 2023. Damien previously served as Founder and CEO of Continental Benefits and owns 40% of the shares outstanding.

Valuation. MRAI is not yet profitable, but trades at 1.4x LTM sales.

Conference Takeaways

- New management is heavily invested in the Company, holding ~61% of shares. Management is focused on improving metrics and reducing costs.
- MRAI is focused on profitable growth, looking to increase topline revenue through organic growth instead of M&A activity in the TPA sector.
- Improved AI algorithm decreasing time to catch future conditions and allowing customers to see savings in 6 months as opposed to over 2 years.
- Management has set a goal of becoming EBITDA profitable in 2025.

For access to full versions of all interviews please visit either mscliffnotes.substack.com or geoinvesting.com/free-trial/.

Disclosures

Analyst Certification

Each authoring analyst of Atrium Research on this report certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated securities discussed (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in the research, (iii) to the best of the authoring analyst's knowledge, she/he is not in receipt of material non-public information about the issuer, (iv) the analyst does not own common shares, options, or warrants in the company under coverage, and (v) the analysts adhere to the CFA Institute guidelines for analyst independence.

Atrium Research Ratings System

BUY: The stock is expected to generate returns of over 20% over the next 24 months.

HOLD: The stock is expected to generate returns of 0-20% over the next 24 months.

SELL: The stock is expected to generate negative returns over the next 24 months.

NOT RATED (N/R): Atrium does not provide research coverage on the respective company.

RATING	COVERED COMPANIES
BUY	21
HOLD	0
SELL	0

About Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. For further information on our team, please visit <https://www.atriumresearch.ca/team>.

General Information

Atrium Research Corporation (ARC) has created and distributed this report. This report is based on information we considered reliable; we have not been provided with any material non-public information by the company (or companies) discussed in this report. We do not represent that this report is accurate or complete and it should not be relied upon as such; further any information in this report is subject to change without any formal or type of notice provided. Investors should consider this report as only one factor in their investment decisions; this report is not intended as a replacement for investor's independent judgment.

ARC is not an IIROC registered dealer and does not offer investment-banking services to its clients. ARC (and its employees) do not own, trade or have a beneficial interest in the securities of the companies we provide research services for and does not serve as an officer or Director of the companies discussed in this report. ARC does not make a market in any securities. This report is not disseminated in connection with any distribution of securities and is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal.

ARC does not make any warranties, expressed or implied, as to the results to be obtained from using this information and makes no express or implied warranties for particular use. Anyone using this report assumes full responsibility for whatever results they obtain. This does not constitute a personal recommendation or take into account any financial or investment objectives, financial situations or needs of individuals. This report has not been prepared for any particular individual or institution. Recipients should consider whether any information in this report is suitable for their particular circumstances and should seek professional advice. Past performance is not a guide for future results, future returns are not guaranteed, and loss of original capital may occur. Neither ARC nor any person employed by ARC accepts any liability whatsoever for any direct or indirect loss resulting from any use of its research or the information it contains.

This report contains "forward looking" statements. Forward-looking statements regarding the Company and/or stock's performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Such statements involve a number of risks and uncertainties such as competition, technology shifts, market demand and the company's (and management's) ability to correctly forecast financial estimates; please see the company's MD&A "Risk Factors" Section for a more complete discussion of company specific risks for the company discussed in this report.

ARC is not receiving any compensation for this report. ARC retains full editorial control over its research content. ARC does not have investment banking relationships and does not expect to receive any investment banking driven income. ARC reports are primarily disseminated electronically and, in some cases, printed form. Electronic reports are simultaneously available to all recipients in any form. Reprints of ARC reports are prohibited without permission. To receive future reports on covered companies please visit <https://www.atriumresearch.ca/research> or subscribe on our website.

The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.